Through the agreement, Leo Pharma’s investigational and approved medicines will be used in combination with Portal’s needle-free drug delivery system.
Portal’s needle-free jet injector platform allows patients to self-administer biologics without needles. It features a reusable, software-controlled handheld injection device and a single-use, pre-filled cartridge to deliver medicine through a pressurized liquid jet, rather than a needle.
“Leo Pharma’s novel therapies in the field of medical dermatology combined with Portal’s innovative approach to drug administration offer hope to people living with debilitating skin diseases,” senior VP of global development at Leo Pharma Christian Antoni said in a news release. “It is our ambition that this collaboration will lead to new and easier ways for people with skin diseases to administer our treatments on their own in the comfort of their home with a needle-free solution.”
“We are excited at the prospect of working closely with Leo Pharma and support their ambition to empower people with skin diseases with a next-generation drug delivery platform for self-administration,” CEO of Portal Patrick Anquetil said. “This commercial collaboration gives us the opportunity to lead with innovation in the field of medical dermatology by combining novel medicines with a patient-preferred needle-free drug delivery system.”